[Treatment of vancomycin-resistant Enterococcus with linezolid in paediatric hospitals]

M Travaglianti1, M Pérez, N Sberna

  • 1Servicio de Farmacia, Hospital de Pediatría Dr. Juan P. Garrahan, Buenos Aires, Argentina. monitravaglianti@yahoo.com.ar

Insights

Linezolid effectively treated vancomycin-resistant Enterococcus infections in critically ill children. While generally well-tolerated, haematological adverse events were noted.

Area of Science:

  • Infectious Diseases
  • Pediatric Pharmacology
  • Antimicrobial Stewardship

Context:

  • Vancomycin-resistant Enterococcus (VRE) poses a significant threat in pediatric healthcare settings.
  • Limited treatment options exist for VRE infections, especially in critically ill children.
  • Linezolid offers a potential therapeutic alternative for VRE infections.

Purpose:

  • To evaluate the efficacy and tolerability of linezolid for treating vancomycin-resistant Enterococcus infections in a pediatric hospital.
  • To describe the clinical outcomes and adverse events associated with linezolid use in pediatric patients with VRE.

Summary:

  • A retrospective study analyzed 15 pediatric patients treated with linezolid for VRE infections between 2002 and 2004.
  • Linezolid demonstrated effectiveness in 11 patients (73.3%), with two treatment failures resulting in death.
  • Hematological adverse events were the most common side effect, occurring in 55.5% of patients.

Impact:

  • Linezolid is an effective and moderately tolerated treatment option for severe VRE infections in children.
  • This study highlights the importance of considering linezolid in the management of VRE in pediatric populations.
  • Further research may explore optimizing linezolid dosing and monitoring for pediatric VRE treatment.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...